Platelet hyperreactivity in diabetes: Focus on GPVI signaling-are useful drugs already available?

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Adults with diabetes are 2-4 times more likely to suffer from heart disease or ischemic stroke than adults without diabetes, yet standard antiplatelet therapy, which is the cornerstone for primary and secondary prevention of cardiovascular disease, fails in many patients with diabetes. Three independent but often interrelated variables that contribute to platelet hyperreactivity-high blood glucose, oxidative stress, and elevated vascular shear forces-coexist in patients with diabetes, creating a perilous concurrence of risk factors for cardiovascular events. Recent research has focused attention on the plateletspecific collagen receptor glycoprotein VI (GPVI) as a potential antithrombotic target. Signaling events downstream of GPVI are influenced by hyperglycemia, oxidative stress, and shear stress. Importantly, drugs targeting these GPVI signaling pathways are already in existence. The potential to repurpose existing drugs is a high-gain strategy for yielding new antiplatelet agents and could have particular benefit in individuals with diabetes.

Original languageEnglish
Pages (from-to)7-13
Number of pages7
JournalDiabetes
Volume66
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017

Cite this

@article{aaeea22b1b3947519615f26a33778299,
title = "Platelet hyperreactivity in diabetes: Focus on GPVI signaling-are useful drugs already available?",
abstract = "Adults with diabetes are 2-4 times more likely to suffer from heart disease or ischemic stroke than adults without diabetes, yet standard antiplatelet therapy, which is the cornerstone for primary and secondary prevention of cardiovascular disease, fails in many patients with diabetes. Three independent but often interrelated variables that contribute to platelet hyperreactivity-high blood glucose, oxidative stress, and elevated vascular shear forces-coexist in patients with diabetes, creating a perilous concurrence of risk factors for cardiovascular events. Recent research has focused attention on the plateletspecific collagen receptor glycoprotein VI (GPVI) as a potential antithrombotic target. Signaling events downstream of GPVI are influenced by hyperglycemia, oxidative stress, and shear stress. Importantly, drugs targeting these GPVI signaling pathways are already in existence. The potential to repurpose existing drugs is a high-gain strategy for yielding new antiplatelet agents and could have particular benefit in individuals with diabetes.",
author = "Arthur, {Jane F.} and Karin Jandeleit-Dahm and Andrews, {Robert K.}",
year = "2017",
month = "1",
day = "1",
doi = "10.2337/db16-1098",
language = "English",
volume = "66",
pages = "7--13",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association",
number = "1",

}

Platelet hyperreactivity in diabetes : Focus on GPVI signaling-are useful drugs already available? / Arthur, Jane F.; Jandeleit-Dahm, Karin; Andrews, Robert K.

In: Diabetes, Vol. 66, No. 1, 01.01.2017, p. 7-13.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Platelet hyperreactivity in diabetes

T2 - Focus on GPVI signaling-are useful drugs already available?

AU - Arthur, Jane F.

AU - Jandeleit-Dahm, Karin

AU - Andrews, Robert K.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Adults with diabetes are 2-4 times more likely to suffer from heart disease or ischemic stroke than adults without diabetes, yet standard antiplatelet therapy, which is the cornerstone for primary and secondary prevention of cardiovascular disease, fails in many patients with diabetes. Three independent but often interrelated variables that contribute to platelet hyperreactivity-high blood glucose, oxidative stress, and elevated vascular shear forces-coexist in patients with diabetes, creating a perilous concurrence of risk factors for cardiovascular events. Recent research has focused attention on the plateletspecific collagen receptor glycoprotein VI (GPVI) as a potential antithrombotic target. Signaling events downstream of GPVI are influenced by hyperglycemia, oxidative stress, and shear stress. Importantly, drugs targeting these GPVI signaling pathways are already in existence. The potential to repurpose existing drugs is a high-gain strategy for yielding new antiplatelet agents and could have particular benefit in individuals with diabetes.

AB - Adults with diabetes are 2-4 times more likely to suffer from heart disease or ischemic stroke than adults without diabetes, yet standard antiplatelet therapy, which is the cornerstone for primary and secondary prevention of cardiovascular disease, fails in many patients with diabetes. Three independent but often interrelated variables that contribute to platelet hyperreactivity-high blood glucose, oxidative stress, and elevated vascular shear forces-coexist in patients with diabetes, creating a perilous concurrence of risk factors for cardiovascular events. Recent research has focused attention on the plateletspecific collagen receptor glycoprotein VI (GPVI) as a potential antithrombotic target. Signaling events downstream of GPVI are influenced by hyperglycemia, oxidative stress, and shear stress. Importantly, drugs targeting these GPVI signaling pathways are already in existence. The potential to repurpose existing drugs is a high-gain strategy for yielding new antiplatelet agents and could have particular benefit in individuals with diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85007316962&partnerID=8YFLogxK

U2 - 10.2337/db16-1098

DO - 10.2337/db16-1098

M3 - Review Article

VL - 66

SP - 7

EP - 13

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 1

ER -